Xenon Stock Faces Worst Day Since 2017 as Lead Drug Proves a Double-Edged Sword

Xenon Pharmaceuticals says it paused trials for azetukalner in major depressive disorder and bipolar depression following ‘adverse events.'

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。